

Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics

Cellanyx Diagnostics News – Announcement of Funding Round

Cellanyx Diagnostics Completes First Close of a Series A1 Funding Round Led By Boston Angel Group

Biotech startup seeking to disrupt cancer diagnostics space raises capital to accelerate product development, continue clinical validations, and expand team

BOSTON, Massachusetts. Nov. 12, 2013. Cellanyx Diagnostics, a biotech startup based out of Boston, today announced the first close of a Series A1 Funding Round led by a Boston angel group. Cellanyx will use the funding to move their product from design and prototyping into a clinical validation phase, and to expand the team. Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution, with a first target indication of prostate cancer diagnosis.

“Cellanyx looks forward to working with its partners to further develop its breakthrough platform. Specifically, Cellanyx is making important clinical gains in the realm of prostate prognostics by creating value for patients, clinicians and our early stakeholders,” says company CEO Dr. Ashok Chander.

Cellanyx’s in vitro diagnostic service will address an unmet need by providing urologists and patients with a predictive and quantitative measure of tumor aggressiveness and metastatic potential to guide personalized therapy. Specifically, Cellanyx will add additional information to the Gleason score, a common metric used in prostate cancer diagnosis. The extra data will reduce uncertainty for physicians, providing more clarity for patients with certain Gleason scores, which will allow for optimized treatment selection.

Cellanyx’s diagnostic platform has the ability to eliminate unnecessary treatment for 140,000 men, potentially saving payers \$4.9 billion per year. To date, Cellanyx has validated its technology in diverse human epithelial tumor lines and in human tumors derived from mouse models of metastasis. Cellanyx’s pre-clinical data has demonstrated a strong correlation with its biomarker output and the growth and invasion potential of cancer cell lines.

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.
One Marina Park Drive,
14th floor
Boston, MA, 02210
Main: 571.212.9991
Email: info@cellanyx.com